Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review - PubMed

Affiliations

• PMID: 25721705
• DOI: 10.1159/000370338

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review

Giovanni A Fava et al. Psychother Psychosom. 2015.

Abstract

Background: Selective serotonin reuptake inhibitors (SSRI) are widely used in medical practice. They have been associated with a broad range of symptoms, whose clinical meaning has not been fully appreciated. Methods: The PRISMA guidelines were followed to conduct a systematic review of the literature. Titles, abstracts, and topics were searched using the following terms: 'withdrawal symptoms' OR 'withdrawal syndrome' OR 'discontinuation syndrome' OR 'discontinuation symptoms', AND 'SSRI' OR 'serotonin' OR 'antidepressant' OR 'paroxetine' OR 'fluoxetine' OR 'sertraline' OR 'fluvoxamine' OR 'citalopram' OR 'escitalopram'. The electronic research literature databases included CINAHL, the Cochrane Library, PubMed and Web-of-Science from inception of each database to July 2014. Results: There were 15 randomized controlled studies, 4 open trials, 4 retrospective investigations, and 38 case reports. The prevalence of the syndrome was variable, and its estimation was hindered by a lack of case identification in many studies. Symptoms typically occur within a few days from drug discontinuation and last a few weeks, also with gradual tapering. However, many variations are possible, including late onset and/or longer persistence of disturbances. Symptoms may be easily misidentified as signs of impending relapse. Conclusions: Clinicians need to add SSRI to the list of drugs potentially inducing withdrawal symptoms upon discontinuation, together with benzodiazepines, barbiturates, and other psychotropic drugs. The term 'discontinuation syndrome' that is currently used minimizes the potential vulnerabilities induced by SSRI and should be replaced by 'withdrawal syndrome'. © 2015 S. Karger AG, Basel.

Similar articles

• Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.

  Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Fava GA, et al. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. Psychother Psychosom. 2018. PMID: 30016772 Review.

• Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

  Black K, Shea C, Dursun S, Kutcher S. Black K, et al. J Psychiatry Neurosci. 2000 May;25(3):255-61. J Psychiatry Neurosci. 2000. PMID: 10863885 Free PMC article. Review.

• SSRI withdrawal syndrome in children and adolescents: a narrative literature review.

  Khan YS, Khoodoruth MAS, Albobali Y, Haddad PM. Khan YS, et al. Expert Opin Drug Saf. 2023 Jan-Jun;22(5):381-390. doi: 10.1080/14740338.2023.2224557. Epub 2023 Jun 20. Expert Opin Drug Saf. 2023. PMID: 37339264 Review.

• Selective serotonin reuptake inhibitor 'discontinuation syndrome' or withdrawal.

  Massabki I, Abi-Jaoude E. Massabki I, et al. Br J Psychiatry. 2021 Mar;218(3):168-171. doi: 10.1192/bjp.2019.269. Br J Psychiatry. 2021. PMID: 31902371

Cited by

• Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

  Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Kennedy SH, et al. Can J Psychiatry. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2. Can J Psychiatry. 2016. PMID: 27486148 Free PMC article. Review.

• Managing Antidepressant Discontinuation: A Systematic Review.

  Maund E, Stuart B, Moore M, Dowrick C, Geraghty AWA, Dawson S, Kendrick T. Maund E, et al. Ann Fam Med. 2019 Jan;17(1):52-60. doi: 10.1370/afm.2336. Ann Fam Med. 2019. PMID: 30670397 Free PMC article.

• Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review.

  Danborg PB, Valdersdorf M, Gøtzsche PC. Danborg PB, et al. Int J Risk Saf Med. 2019;30(2):59-71. doi: 10.3233/JRS-180046. Int J Risk Saf Med. 2019. PMID: 30714974 Free PMC article.

• Virtual controls as an alternative to randomized controlled trials for assessing efficacy of interventions.

  Strayhorn JM Jr. Strayhorn JM Jr. BMC Med Res Methodol. 2021 Jan 5;21(1):3. doi: 10.1186/s12874-020-01191-9. BMC Med Res Methodol. 2021. PMID: 33402097 Free PMC article. Review.

• The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition.

  Guy A, Brown M, Lewis S, Horowitz M. Guy A, et al. Ther Adv Psychopharmacol. 2020 Nov 9;10:2045125320967183. doi: 10.1177/2045125320967183. eCollection 2020. Ther Adv Psychopharmacol. 2020. PMID: 33224468 Free PMC article.

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • S. Karger AG, Basel, Switzerland

• Other Literature Sources

  • figshare - Data